You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 8, 2025

Details for Patent: 9,649,306


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,649,306
Title:Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide
Abstract: The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide. Novel solid forms of this compound, their utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing them are also object of the present invention.
Inventor(s): Barbugian; Natale Alvaro (Milan, IT), Forino; Romualdo (Milan, IT), Fumagalli; Tiziano (Trezzano Rosa, IT), Orsini; Paolo (Legnano, IT)
Assignee: NERVIANO MEDICAL SCIENCES S.R.L. (Nerivano (MI), IT)
Application Number:15/172,478
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,649,306: A Detailed Analysis

Introduction

Patent 9,649,306, like any other patent, is a complex document that outlines the scope and claims of an invention. To understand its significance and implications, it is crucial to delve into the patent's specifics, the broader patent landscape, and recent updates in patent law, particularly those related to AI and technology.

Patent 9,649,306 Overview

Patent Title and Abstract

While the specific details of Patent 9,649,306 are not provided here, a typical patent includes a title, abstract, background of the invention, summary of the invention, and detailed descriptions of the drawings and claims.

Claims Analysis

The claims section is the most critical part of a patent, as it defines the scope of the invention. Here, each claim must be clear, concise, and supported by the description and drawings. The claims can be divided into independent and dependent claims, with independent claims standing alone and dependent claims referring back to an independent claim[3].

Patent Scope and Claim Language

Metrics for Measuring Patent Scope

Research has shown that patent scope can be measured using simple metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes[3].

Impact of Claim Language

The language used in claims is vital. Narrower claims are associated with a higher probability of grant and a shorter examination process compared to broader claims. This highlights the importance of drafting claims that are specific and well-defined to avoid rejections and litigation issues[3].

Recent Updates in Patent Law: AI and Technology

2024 USPTO Guidance Update on AI Patents

The USPTO's 2024 guidance update, prompted by Executive Order 14110, aims to clarify the process for determining the patent eligibility of AI-related inventions. This update is significant for innovators and patent practitioners:

Evaluating Practical Applications

The guidance emphasizes evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Incorporation of Recent Case Law

The guidance integrates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations. This helps promote consistency and clarity in the application of patent eligibility criteria, reflecting the latest judicial thinking[1].

New Examples for AI Technologies

The USPTO has introduced new examples specifically tailored to AI technologies. For instance, Example 48 illustrates how claims involving specific applications of AI, such as improving the accuracy of voice commands in a hands-free environment, can meet the eligibility criteria by demonstrating a practical application[1].

Real-World Applications and Practical Utility

Demonstrating Concrete Benefits

To bolster the argument for patent eligibility, it is crucial to demonstrate how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field. This involves highlighting the real-world applications of the claimed method or system, showing how it improves technology or provides a practical application[1].

Example Analysis

In the context of Patent 9,649,306, if the claims involve AI or other technological innovations, they must be analyzed to ensure they meet the criteria for patent eligibility. For example, if a claim involves an AI system designed to improve speech recognition, it must specify how this system is used in a practical application, such as enhancing the accuracy of voice commands in hands-free environments, to be considered patent-eligible[1].

Patent Landscape and Trends

Probability of Receiving a US Patent

Historical data shows that the probability of receiving a US patent varies based on several factors, including the technology field and the entity size of the applicant. For instance, applications from large entities may have different outcomes compared to those from small entities[4].

Small Claims Patent Court

There is ongoing discussion about the feasibility of a small claims patent court, which could impact the patent landscape by providing a more accessible and cost-effective way for smaller entities to resolve patent disputes. This initiative is being studied by the Administrative Conference of the United States (ACUS) in collaboration with the USPTO[5].

Key Takeaways

  • Clear and Specific Claims: The language used in claims is critical for determining patent eligibility and avoiding rejections.
  • Practical Applications: Claims must integrate judicial exceptions into practical applications to be considered patent-eligible.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution.
  • Recent Case Law: The 2024 USPTO guidance update incorporates recent Federal Circuit decisions to ensure consistency and clarity in patent eligibility criteria.
  • Real-World Applications: Highlighting the real-world applications and concrete benefits of the claimed method or system is essential for demonstrating patent eligibility.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The 2024 USPTO guidance update clarifies the process for determining the patent eligibility of AI-related inventions, emphasizing the integration of judicial exceptions into practical applications and ensuring AI-assisted inventions are evaluated on equal footing with other technologies.

How do recent case law and examples impact AI patent claims?

Recent case law and examples, such as those provided in the 2024 USPTO guidance, help promote consistency and clarity in the application of patent eligibility criteria. These examples illustrate how AI-related claims can meet eligibility criteria by demonstrating practical applications.

What metrics are used to measure patent scope?

Patent scope can be measured using metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments and forward citations.

How does the use of AI in invention development affect patent eligibility?

The use of AI in invention development does not impact subject matter eligibility, provided there is significant human contribution. The focus remains on the claimed invention itself rather than the method of development.

What is the current status of the small claims patent court initiative?

The Administrative Conference of the United States (ACUS) is conducting a study on the feasibility and structure of a small claims patent court, with ongoing public comments and stakeholder input.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims and Patent Scope - SSRN
  4. What Is the Probability of Receiving a US Patent? - YJOLT
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,649,306

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Subscribe
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Subscribe
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Subscribe
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,649,306

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
12169139May 23, 2012

International Family Members for US Patent 9,649,306

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 091138 ⤷  Subscribe
Australia 2013265288 ⤷  Subscribe
Australia 2018201037 ⤷  Subscribe
Brazil 112014028841 ⤷  Subscribe
Canada 2873979 ⤷  Subscribe
China 104395308 ⤷  Subscribe
China 106167485 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.